Helping patients get started

Download quick reference sheets that include a product’s DIN and what patients can find on BiogenTherapies.ca.

Patients will need their DIN to access the site.

Add the website to your bookmarks for quick access!

TECFIDERA (dimethyl fumarate) is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the progression of disability.

Consult the product monograph at www.biogen.ca/products/TECFIDERA_PM_EN for contraindications, warnings, precautions, adverse reactions, drug interactions and dosing. The Product Monograph is also available by contacting Biogen Canada Inc. at 1-866-359-2502.

TYSABRI (natalizumab) is indicated as monotherapy (i.e. single disease-modifying agent) for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.

Consult the product monograph at www.biogen.ca/products/tysabri_pm_EN.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by contacting Biogen Canada Inc. at 1-866-359-2502.

PLEGRIDY is indicated for the treatment of relapsing remitting multiple sclerosis (RRMS) for adult patients

  • to reduce the frequency of clinical exacerbations
  • to slow the progression of disability

Consult the product monograph at https://www.biogen.ca/products/PLEGRIDY_PM_EN.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by contacting Biogen Canada Inc. at 1-866-359-2502.

AVONEX PS/AVONEX PEN is indicated for:

  • Treatment of relapsing forms of multiple sclerosis (MS)
    • To slow the progression of disability
    • To decrease the frequency of clinical exacerbations
    • To reduce the number and volume of active brain lesions identified on Magnetic Resonance Imaging (MRI) scans
  • A subgroup of relapsing MS includes secondary progressive MS (SPMS) patients who are still experiencing relapses, also known as relapsing progressive MS (RPMS)
  • Treatment of people who have experienced a single demyelinating event, accompanied by abnormal MRI scans, with lesions typical of MS:
    • To delay the onset of clinically definite MS (as determined by a second demyelinating event);
    • To decrease the number and volume of active brain lesions and overall disease burden (as identified by MRI scans). Before initiating treatment with AVONEX PS/AVONEX PEN, alternate diagnoses should first be excluded.

Consult the product monograph at www.biogen.ca/products/AVONEX_PM_EN.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by contacting Biogen Canada Inc. at 1-866-359-2502.

 

Biogen-105098